OHRP

  0%
Previous Close
Open
Price To Book
Market Cap 0
Shares 0
Volume 0
Short Ratio
Av. Daily Volume 0

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released January 5, 2017 - primary endpoint not met.
OHR-102 (MAKO)
Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase 2 data released July 2015
OHR-102
Retinal vein occlusion (CRVO)

Latest News

  1. NeuBase Therapeutics Closes Merger Transaction with Ohr Pharmaceutical
  2. Ohr Pharmaceutical, Inc. Announces Stockholder Approval of Merger Agreement with NeuBase Therapeutics, Inc.
  3. Ohr Pharmaceutical Urges Stockholders to Vote “FOR” Merger with NeuBase Therapeutics at Special Meeting on July 10, 2019
  4. NeuBase Therapeutics Designates Industry Leaders to Board of Directors 
  5. Ohr Pharmaceutical Reports Financial Results for the Fiscal Second Quarter of 2019
  6. Rigrodsky & Long, P.A. Files Class Action Suit Against Ohr Pharmaceutical, Inc.
  7. NeuBase Therapeutics Announces Agreements for $9 Million Financing
  8. Four Tech Stocks To Watch on Wednesday
  9. Ohr Pharmaceutical Regains Compliance with NASDAQ Listing Requirements
  10. Ohr Pharmaceutical Reports Financial Results for the Fiscal First Quarter of 2019
  11. Lifshitz & Miller LLP Announces Investigation of CAS Medical Systems, Inc., Entegra Financial Corp., Fidelity Southern Corporation, First Data Corporation, Kinderhook Bank Corp., Maxwell Technologies, Inc., Ohr Pharmaceutical, Inc., and Owens Realty Mortgage, Inc.
  12. OHR PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Ohr Pharmaceutical, Inc. - OHRP
  13. The Daily Biotech Pulse: Partial Clinical Hold On Advaxis Cervical Cancer Drug, Ohr's Reverse Split, Ironwood Starts Phase 1 Trial
  14. Ohr Pharmaceutical Announces Reverse Stock Split to be Effective February 4, 2019
  15. INVESTOR ALERT: Monteverde & Associates PC is Investigating the Recently Announced Merger
  16. SHAREHOLDER ALERT: WeissLaw LLP Investigates Ohr Pharmaceutical, Inc.
  17. OHR PHARMACEUTICAL INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Ohr Pharmaceutical, Inc. - OHRP
  18. OHR PHARMACEUTICAL, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Merger
  19. Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of OHR Pharmaceutical, Inc. (OHRP) on Behalf of Stockholders and Encourages OHRP Investors to Contact the Firm
  20. Here's more about what could be Pittsburgh's next public company